SEC Filing Summary: Ekso Bionics Holdings, Inc. (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 20, 2026, by Ekso Bionics Holdings, Inc. (Nasdaq: EKSO). The report details a material definitive agreement entered into on January 20, 2026, and closed on January 22, 2026, involving a private placement of equity securities.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of Series B Convertible Preferred Stock and Warrants.
- Securities Issued:
- 5,852 shares of Series B Convertible Preferred Stock (Stated Value: $1,000/share).
- Warrants to purchase up to 355,960 shares of Common Stock.
- Conversion Terms: Preferred stock converts to 711,922 shares of Common Stock at a price of $8.22 per share.
- Warrant Terms: Exercise price of $8.22 per share; exercisable starting July 22, 2026.
- Net Proceeds: Approximately $5.3 million after deducting fees and expenses.
- Placement Agent Fees: 6.0% of gross proceeds (approx. $0.4 million) plus a warrant for 14,238 shares.
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and Corporate Actions
The filing reports the entry into a Securities Purchase Agreement and a Registration Rights Agreement. The Company filed a Certificate of Designation with the State of Nevada to create the Series B Preferred Stock. The transaction includes a lock-up provision preventing transfer or short sales for six months post-closing or until a change of control, whichever is earlier. A registration statement for the resale of conversion shares and warrant shares must be filed by June 1, 2026.
Outlook, Risks, and Contingencies
- Dilution Limits: Conversion and warrant exercise are subject to beneficial ownership limits (9.99% individually, 19.99% collectively) to prevent excessive dilution.
- Protective Provisions: Holders of Series B Preferred Stock have veto rights over actions that adversely affect their rights, including the issuance of senior stock or amendments to the charter.
- Redemption: Shares are redeemable at Stated Value starting one year after closing or upon a "Trading Failure."
- Financial Data: The filing does not provide specific revenue, profit, cash flow, or debt metrics for the reporting period; it focuses solely on the capital raise.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received (reported as expected $5.3 million).
- Review the full text of the Certificate of Designation (Exhibit 3.1) for specific redemption triggers and voting thresholds.
- Monitor the filing of the registration statement by the June 1, 2026 deadline to ensure liquidity for the new shares.
- Assess the impact of the 711,922 conversion shares and 355,960 warrant shares on fully diluted share count.
- Confirm the identity of the institutional and accredited investors participating in the placement.